Showing 3601-3610 of 4164 results for "".
- Tenpoint Therapeutics Appoints Stephen S. Lane, MD, as Chief Medical Officerhttps://modernod.com/news/tenpoint-therapeutics-appoints-stephen-s-lane-md-as-chief-medical-officer/2486536/Tenpoint Therapeutics announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the company’s executive leadership team and oversee clinical development strategy, medical affairs, and pharmacovigilance. <
- Viridian Reports Positive Phase 3 Data for Subcutaneous TED Therapy, Eyes Regulatory Filinghttps://modernod.com/news/viridian-reports-positive-phase-3-data-for-subcutaneous-ted-therapy-eyes-regulatory-filing/2486438/Key Takeaways Viridian’s Phase 3 REVEAL-1 trial met its primary endpoint, showing statistically significant and clinically meaningful reductions in proptosis with subcutaneous eleg
- Vital Tears and Brightstar Therapeutics Form Joint Medical Advisory Boardhttps://modernod.com/news/vital-tears-and-brightstar-therapeutics-form-joint-medical-advisory-board/2486040/Vital Tears and Brightstar Therapeutics have announced the formation of a joint Medical Advisory Board, bringing together nine leaders in ophthalmology and optometry to help guide the organizations’ expanding clinical and scientific initiatives.
- BostonSight Announces Leadership Changes to Advance Ocular Surface Care Worldwidehttps://modernod.com/news/bostonsight-announces-leadership-changes-to-advance-ocular-surface-care-worldwide/2485722/BostonSight announced a 5-year strategic roadmap designed to redefine ocular surface treatment through advancements in clinical research, professional education, and specialty lens technology. As part of the plan, BostonSight announced a new leadership structure ai
- iVeena Doses First Participant in Phase 1 Trial of IVMED-85 for Myopia Progressionhttps://modernod.com/news/iveena-doses-first-participant-in-phase-1-trial-of-ivmed-85-for-myopia-progression/2485668/iVeena Delivery Systems announced that the first patient has been dosed in its phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers. The phase 1 trial is designed to evaluate the safety and tolerabili
- Orasis Pharmaceuticals Presents New Data Showing Qlosi Is Pupil Selective in Presbyopic Eyeshttps://modernod.com/news/orasis-pharmaceuticals-presents-new-data-showing-qlosi-is-pupil-selective-in-presbyopic-eyes/2485470/Orasis Pharmaceuticals announced new clinical data demonstrating that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective, significantly reducing pupil diameter without a statistically significant change in ciliary muscle response in presb
- Topcon Healthcare Launches IDHea to Advance Digital Research in Eye Care and Oculomicshttps://modernod.com/news/topcon-healthcare-launches-idhea-to-advance-digital-research-in-eye-care-and-oculomics/2484202/Topcon Healthcare announced the launch of IDHea Inc., the Institute for Digital Health, a new company dedicated to transforming clinical research in eye care and the emerging field of oculomics—the study of ocular biomarkers that reflect systemic health.
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- OKYO Pharma Secures Funding to Advance Urcosimod for Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-secures-funding-to-advance-urcosimod-for-neuropathic-corneal-pain/2482926/OKYO Pharma announced it has received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, the company’s lead candidate for treating Neuropathic Corneal Pain (NCP) “Neur